What is Acino Holding AG Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Acino Holding AG's annualized net income for the quarter that ended in Dec. 2013 was €-14.5 Mil. Acino Holding AG's average shareholder tangible equity for the quarter that ended in Dec. 2013 was €108.5 Mil. Therefore, Acino Holding AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2013 was -13.37%.
The historical rank and industry rank for Acino Holding AG's Return-on-Tangible-Equity or its related term are showing as below:
FRA:S3H'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -13.46 Med: 9.27 Max: 107.09
Current: -13.46
During the past 11 years, Acino Holding AG's highest Return-on-Tangible-Equity was 107.09%. The lowest was -13.46%. And the median was 9.27%.
FRA:S3H's Return-on-Tangible-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 6.31
vs FRA:S3H: -13.46
Acino Holding AG Return-on-Tangible-Equity Historical Data
The historical data trend for Acino Holding AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acino Holding AG's Return-on-Tangible-Equity
For the Drug Manufacturers - General subindustry, Acino Holding AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acino Holding AG's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Acino Holding AG's Return-on-Tangible-Equity falls into.
Acino Holding AG Return-on-Tangible-Equity Calculation
Acino Holding AG's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2013 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Dec. 2013) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Acino Holding AG (FRA:S3H) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Acino Holding AG Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Acino Holding AG's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:S3H has been successfully added to your 